The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
so in the diabetics it's a permanent storage with very little turnover while in the atlet it's a substrate source that is constantly being used and so the use the turnover of that that that substrate is the important factor driving towards insulin resistance or actually insulin sensitivity
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
in the case of the person with type 2 diabetes that intramyocellular lipid store is indeed just that it is a Depot it is a place where excess energy is seeping out of seeping out of adapost tissue and remaining stored in the muscle and in fact as we saw in our podcast a couple years ago with Gerald Schuman that's one of the Hallmarks of the Cascade of events that leads to insulin resistant